Regenerative Biotechnology
Double Checkpoint Natural Killer Cells
Heterologous Natural Killer cells with dual immune checkpoint blockade for antitumor therapy.
Injectable solution of heterologous Natural Killer cells pretreated with nivolumab and ipilimumab, enhancing innate and adaptive immune response against tumor cells.
Composition
Heterologous Natural Killer cells, nivolumab and ipilimumab.
Pharmaceutical form
Injectable solution.
Presentation
Single-dose vial, 4 ml.
Therapeutic properties
Antitumor cytotoxic activity through activation of heterologous NK cells and blockade of PD-1 and CTLA-4 immune checkpoints.
- Recognition of tumor cells.
- Induction of tumor apoptosis.
- Blockade of immune evasion.
- Increased antitumor cytotoxicity.
- Activation of innate immunity.
- Enhancement of adaptive response.
- Reduction of tumor growth.
- Immunological functional consistency.
Mechanism of action & Clinical data
NK cells induce tumor cytotoxicity and, through PD-1 and CTLA-4 blockade, enhance the antitumor immune response.